What is perimenopause, really?

Menopause is one day. Perimenopause is the years before it — and it can start much earlier than most women are told.

Here is what almost nobody explains clearly. Menopause is not a phase. It is a single point in time: the day that marks twelve consecutive months without a period. Everything before that day — the fluctuating hormones, the unpredictable symptoms, the cycle changes — is perimenopause.

And perimenopause can last anywhere from two to twelve years.

During this transition, your ovaries gradually reduce their production of oestrogen and progesterone. But they don't do this in a smooth, predictable decline. Oestrogen levels can be higher than normal one week and significantly lower the next. It is this erratic fluctuation — not simply the decline itself — that drives most perimenopausal symptoms.

Oestrogen has receptors across almost every system in your body. Your brain, your bones, your heart, your bladder, your skin, your joints. When oestrogen signals become inconsistent, the effects are felt everywhere simultaneously. This is why the symptom picture of perimenopause is so wide-ranging — and why it is so frequently misunderstood as several unrelated problems rather than one central process.

Perimenopause can begin as early as the mid-thirties. One in one hundred women reaches menopause before the age of 40 — a condition called Premature Ovarian Insufficiency, which requires specific and more urgent clinical attention.

Because there is no single reliable test. FSH levels — Follicle Stimulating Hormone — fluctuate significantly during perimenopause, meaning a single normal reading does not rule it out. The British Menopause Society is clear that diagnosis should be clinical, based on symptoms and age, not dependent on blood tests alone.

A survey of 4,432 US women by Cunningham et al. (2025) in npj Women's Health found significant symptom burden even in women aged 30 to 45 — and high rates of under-recognition. Many felt unprepared. Many had seen multiple clinicians before receiving any acknowledgement that what they were experiencing might be hormonally driven.

If that is your experience, you are not alone. And you are not imagining it.

The 34 symptoms — what's really going on

It is not 34 separate problems. It is one central process — hormonal fluctuation — affecting almost every system in your body at once.

You may have seen the phrase "the 34 symptoms of menopause." While this is not a precise clinical list, it captures something important: perimenopause does not stay in one place. It moves through the body.

The reason is oestrogen. During your reproductive years, oestrogen has been active not just in your reproductive system but in your brain, your bones, your cardiovascular system, your bladder, your joints, your skin. It has receptors across almost every tissue type. When oestrogen begins to fluctuate unpredictably — as it does throughout perimenopause — the effects are felt everywhere, often simultaneously.

Hot flushes and night sweats are the symptoms most commonly associated with perimenopause — and they are genuinely prevalent. But the symptoms most frequently missed, most frequently dismissed, and most frequently misdiagnosed are the psychological ones.

Anxiety that arrives without obvious cause. Mood changes that feel disproportionate to circumstances. Irritability, low motivation, difficulty concentrating, brain fog, a sense of not being yourself. These are perimenopausal symptoms. They have a biological mechanism. Oestrogen fluctuation disrupts serotonin, dopamine, and GABA pathways in the brain — the same neurotransmitter systems involved in mood regulation and anxiety. This is not a personality change. It is a neurological one.

Joint pain, muscle aches, and stiffness are among the least-discussed perimenopausal symptoms — yet research published in Menopause (2026) found that 70% of women report musculoskeletal symptoms during the menopause transition. Oestrogen receptors are present in bone, cartilage, synovial membranes, and muscle tissue. When oestrogen declines, all of these are affected.

In some Southeast Asian and South Asian populations, joint pain is reported more frequently than vasomotor symptoms — making it not only common but, in some groups, the dominant presenting symptom.

The hypothalamus — the brain region that controls body temperature — also regulates sleep, appetite, stress response, and mood. This is why hot flushes, sleep disruption, anxiety, and irritability so often arrive together. They share a common controller, and oestrogen fluctuation destabilises that controller.

Understanding this matters. When symptoms are treated in isolation — a sleeping tablet here, an antidepressant there — the underlying hormonal mechanism remains unaddressed. The goal is not to manage each symptom individually. It is to understand what is driving all of them.

HRT: what the evidence actually says

The fear came from a flawed study in 2002. Here is what twenty years of better research — and the British Menopause Society — actually say.

In 2002, the Women's Health Initiative published results suggesting that HRT caused breast cancer and cardiovascular disease. The headlines were dramatic. Prescriptions collapsed. Millions of women stopped treatment or never started it.

The problem was the study design. The WHI enrolled predominantly older women — average age 63 — who had been postmenopausal for over a decade before starting HRT. They were given oral synthetic hormones. The findings from that specific population, using those specific formulations, were then applied wholesale to all women, of all ages, using all forms of HRT. That extrapolation was scientifically unjustified.

The British Menopause Society Fast Facts on HRT and Breast Cancer Risk (September 2025) summarises the current evidence clearly. For oestrogen-only HRT — used by women who have had a hysterectomy — there is little or no change in breast cancer risk. For combined HRT, there may be a small duration-dependent increased risk: approximately 4 additional cases per 1,000 women over 5 years for those aged 50 to 59.

To put that in context: the BMS infographic shows that drinking two or more units of alcohol per night is associated with 5 additional cases per 1,000 women. Being overweight or obese: 24 additional cases. Taking at least 2.5 hours of moderate exercise per week: 7 fewer cases.

Not all HRT carries the same risk profile. Oral oestrogen is processed through the liver, which increases clotting factor production and is associated with a small increased risk of venous thromboembolism. Transdermal oestrogen — patches, gels, sprays — bypasses the liver and is not associated with increased VTE risk, according to BMS guidance. For women with any VTE risk factors, transdermal is strongly preferred.

And progestogen type matters too

Your joints, muscles and bones in perimenopause

70% of women report musculoskeletal symptoms during the menopause transition. Almost none of them are told that oestrogen is the reason.

The aching knees that appeared from nowhere. The stiffness in your hands in the morning. The shoulder that seized up without injury. The joints that just feel different to how they used to feel.

For many women, these symptoms arrive during perimenopause and are attributed to age, overuse, or general wear and tear. Rarely is the connection to oestrogen made — despite the fact that research published in Menopause (2026) reports that 70% of women experience musculoskeletal symptoms during the menopause transition, and in some South and Southeast Asian populations, joint pain is reported more frequently than hot flushes.

Oestrogen plays an active role in joint health. It modulates inflammation, supports cartilage integrity, and influences the activity of the cells that build and break down bone tissue. When oestrogen fluctuates and declines during perimenopause, all of these processes are disrupted.

Bone density loss accelerates during the perimenopause transition — particularly in the lumbar spine. This is the beginning of the process that, left unaddressed, can contribute to osteoporosis and fracture risk in later life. Research shows that the most rapid bone loss occurs in the years immediately surrounding the final menstrual period.

Joint pain during perimenopause tends to affect multiple joints rather than one in isolation, without obvious swelling or inflammatory markers. There are no specific biomarkers for it. It presents in the context of other perimenopausal symptoms — sleep disruption, vasomotor symptoms, mood changes — which is one reason it is so frequently missed as hormonally driven.

The evidence is consistent on this: resistance training is non-negotiable. Progressive strength training preserves muscle mass, supports bone density, reduces joint pain, and improves insulin sensitivity — all simultaneously. Low-impact, high-intensity exercise can protect joints while building the muscle that supports them.

Protein intake matters too. Muscle protein synthesis becomes less efficient with age and hormonal change, meaning perimenopausal women typically need more dietary protein than they did in their thirties to maintain the same muscle mass.

And hormone therapy may have a role. The WHI data showed that women receiving HRT reported more relief from joint symptoms than those receiving placebo, and HRT was associated with a significant reduction in new musculoskeletal symptoms. Large-scale RCTs specifically addressing musculoskeletal outcomes are still needed — but the signal is there.

Your joints are not just ageing. They are responding to a hormonal environment that has changed. That distinction matters — because it changes what you can do about it.